Reply to the Editor  by Samuels, Louis
successful management of acute necrotiz-
ing eosinophilic myocarditis (ANEM) with
a biventricular assist device (BIVAD) and
steroids.
ANEM is indeed a dramatic condition
often leading to a fatal issue unless promptly
managed with circulatory support and steroid
administration.2 Endomyocardial biopsy is
essential to diagnosis confirmation and rapid
therapeutic choice making.
The particularity of ANEM is rapid and
spectacular circulatory improvement when
steroids are administered early enough.2
Therefore, we think that a BIVAD is prob-
ably too aggressive and that a far less-
invasive mean, such as extracorporeal life
support (ECLS), is more appropriate for
such a condition.
One month ago, we had a case similar to
that described by Kohout and colleagues.1
A 19-year-old woman presented to our de-
partment with abrupt onset of congestive
heart failure and respiratory distress. She
had been already intubated before admis-
sion, and echocardiography showed a much
altered heart function, with moderately di-
lated left and right ventricles, and a left
ventricular ejection fraction of less then 10%.
Computed tomography scan ruled out pul-
monary embolism and confirmed severe pul-
monary edema. The girl had an unremark-
able medical history, with no proof of drug
abuse or medications. She had no other
symptoms suggesting a preexisting disor-
der except for mild abdominal pain 1 day
earlier. Blood examination results showed
no particularity. Serologic and polymerase
chain reaction screening results for viral or
other infectious diseases returned to normal
later on.
In this context of severe congestive heart
failure, a femoro-femoral ECLS was insti-
tuted in the special care unit at the patient’s
bedside, with a blood output of 3.5 L/mn.
Inotropic support with norepinephrine and
dobutamine was also started. Adequate un-
loading of the left and right-sided heart
chambers was assessed with a Swan–Ganz
catheter and echocardiography.
On day 1, chest radiography showed a
great reduction of the pulmonary edema
(Figure 1). An endomyocardial biopsy was
performed, which confirmed the diagnosis
of ANEM on day 2. Steroids were imme-
diately begun. The improvement was spe-
tacular. As soon as day 6, echocardiogra-
phy showed marked improvement of the
cardiac function. Weaning from ECLS was
begun on day 7 and removed on day 10.
Cardiac echocardiography showed a com-
pletely normalized left ventricular func-
tion. The patient was discharged from the
special care unit on day 13.
When ANEM is suspected, we think
that ECLS is an excellent device for first-
line circulatory support. Prompt endomyo-
cardial biopsy is mandatory to confirm the
diagnosis and initiate intravenous steroids.
This offers the advantage of avoiding the
primary use of a far more aggressive mean
of circulatory support, such as a BIVAD, in
a condition that is likely to respond rapidly
and favorably to steroids. In case the bi-
opsy rules out ANEM, then ECLS, if in-
sufficient, could be removed, and other
more aggressive means of circulatory sup-
port instituted.3
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Reply to the Editor:
We thank Dr Khabbaz and colleagues for
their contribution to the management of
acute necrotizing eosinophilic myocarditis
with mechanical circulatory assist. In our
article,1 we make no attempt to suggest that
ventricular assist device (VAD) support is
the only method by which to properly man-
age the disease. On the contrary, we rec-
ognize the fact that this is a life-threatening
disorder on the one hand, but responsive to
steroid therapy on the other. Treatment
strategies have ranged from steroid therapy
alone2 to transplantation.3 The main mes-
sage in our article and others is to support
the circulation while the diagnosis is made
and treatment is initiated. The precise
method by which to accomplish these ends
varies according to the condition of the
patient at the time of presentation, the tools
and technologies available at the treating
Figure 1. Chest x-ray film before ECLS (left). It was done on the admission of the patient
and shows bilateral pulmonary edema and heart enlargement, with a cardiothoracic index
of 0.60. Chest x-ray film 1 day after ECLS institution (right). Pulmonary edema is already
greatly reduced, and cardiothoracic index decreased to 0.45.
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institution, and the response to steroids.
Not every case will be diagnosed antemor-
tem, and not every pathology will respond
favorably to steroids. Thus, treatment must
take into consideration the possibility that
bridge to recovery or bridge to transplant
is conceivable. VAD support, therefore, is
an excellent tool to accomplish the goal—
particularly with a VAD that has features
such as short- or long-term support, bridge
to recovery or transplant, ambulation with
possibility for home discharge, and so
forth. In addition, a VAD that has left ven-
tricular (LV) apical cannulation allows for
optimal unloading of the LV while on sup-
port, antegrade flow pattern, and pulsatile
flow. Although extracorporeal life support
(ECLS) has been used extensively for acute
circulatory decompensation, the femoral–
femoral circulation is suboptimal in terms
of resting the LV and counterproductive
when the LV recovers and weaning is
attempted—there is conflicting flow from
the heart antegrade and femoral flow retro-
grade. Furthermore, extracorporeal mem-
brane oxygenation introduces an oxygen-
ator, which is appropriate when lung injury
is associated with the heart condition but
potentially detrimental when it is not. In
addition, femoral cannulation is associated
with the potential for vascular complica-
tions (both venous and arterial), prevents
movement of the patient in the bed or at the
bedside, and limits flow by the relatively
small size of the cannulae. These views
were shared by other surgeons in a discus-
sion of acute heart failure with various
types of mechanical circulatory assist tech-
nologies.4
We congratulate Dr Khabbaz and his
team for their wonderful success and en-
courage others to think about mechanical
circulatory support when confronted with a
severe case of acute necrotizing eosino-
philic myocarditis. The use of ECLS is not
an unreasonable method to rapidly restore
circulatory stability. However, in the event
that ECLS is insufficient, then a more ad-
vanced form of mechanical circulatory sup-
port, such as a VAD, is appropriate.
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Modern drainage techniques include
not only smaller drains for pain
reduction
To the Editor:
In a prospective, randomized, controlled trial,
Roberts and colleagues1 recently demon-
strated that the performance of small-bore
Blake drains (19F) (Ethicon Inc, Somerville,
NJ) is not inferior to that of standard Portex
drains (28F) (Portex, Inc, Hythe, Kent, UK)
after cardiac surgery. The study provides im-
portant evidence on the efficacy of modern
drainage techniques. However, we have
some comments.
The authors compared 199 patients un-
dergoing first-time cardiac procedures; 90
patients received Blake drains, and 109 pa-
tients received standard Portex drains. We
are not convinced that the influence of
complex valve procedures, which are more
frequent in the Blake group, is not statisti-
cally relevant. Furthermore, we believe that
a homogenous patient group might demon-
strate the advantage of silastic Blake drains
and allow extrapolation to other patient
groups.
Akowuah and colleagues2 demonstrated
less pain with Blake drains, but, as men-
tioned by Roberts and colleagues,1 with
only a small patient group (70 patients with
35 in each group). Therefore, it is a pity
that the authors did not assess pain with a
visual analog scale score, which is easy to
perform.
Finally, the authors somehow misquoted
our correspondence on the article by Barnard
and colleagues:3 We do not believe that “. . .
the only way to reduce patient discomfort is
to use smaller and softer drains.” In fact, we
stated that a modern drainage technique is a
fundamental part in pain reduction while re-
moving drains after thoracic and cardiac sur-
gery. Of course, analgesia, special removal
maneuvers, and so forth have value, as dem-
onstrated in various studies.4 In our unit, 10F
to 19F Blake drains are used in all patients
(1800 patients/year). Our observations are
consistent with the literature: The Blake drain
system is as effective as conventional drains
with no increased risk of retained blood in the
chest or tamponade and significantly less
pain for the patient. We therefore advocate
the use of Blake drains in patients undergoing
thoracic or cardiac surgery as well.
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Reply to the Editor
We thank Dr Mair and colleagues for their
interest in our study1 and for their com-
ments to which we would like to reply.
First, we agree that homogenous patient
groups avoid confounding variables; the
influence of complex valve procedures is
one that was mentioned. However, we do
not agree that it was the heterogeneity of
the patient groups that prevented us from
demonstrating an advantage of the Blake
system (Ethicon Inc, Somerville, NJ). Our
study was powered on the statistical basis
of testing noninferiority, which allows sta-
tistical comparison with a predefined level
of difference between groups. Had the
study hypothesis been that Blake drains
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